Enhancing breast milk production with Domperidone in mothers of preterm neonates (EMPOWER trial)
1 Department of Newborn & Developmental Paediatrics, University of Toronto, Centre for Mother, Infant, Child Research, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
2 IWK Health Centre, Dalhousie University, Halifax, NS, Canada
3 Perinatal and Women’s Health, London Health Sciences Centre, London, ON, Canada
4 Sunnybrook Research Institute, University of Toronto, Toronto, Canada
5 Pharmacy Services, London Health Sciences Centre, London, Canada
6 Department of Pharmacology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
BMC Pregnancy and Childbirth 2012, 12:87 doi:10.1186/1471-2393-12-87Published: 31 August 2012
The use of mother’s own breast milk during initial hospitalization has a positive impact not only in reducing potential serious neonatal morbidities but also contribute to improvements in neurodevelopmental outcomes. Mothers of very preterm infants struggle to maintain a supply of breast milk during their infants’ prolonged hospitalization. Galactogogues are medications that induce lactation by exerting its effects through oxytocin or prolactin enhancement. Domperidone is a potent dopamine D2 receptor antagonist which stimulates the release of prolactin. Small trials have established its ability in enhancing breast milk production. EMPOWER was designed to determine the safety and efficacy of domperidone in mothers experiencing an inadequate milk supply.
EMPOWER is a multicenter, double masked, randomized controlled phase-II trial to evaluate
the safety and effectiveness of domperidone in those mothers identified as having
difficulty in breast milk production. Eligible mothers will be randomized to one of
two allocated groups: Group A: domperidone 10 mg orally three times daily for 28 days; and Group B: identical placebo 10 mg orally three times daily for 14 days followed by domperidone
10 mg orally three times daily for 14 days. The primary outcome will be determined
at the completion of the
first 2-week period; the second 2-week period will facilitate answering the secondary questions regarding
timing and duration of treatment. To detect an estimated 30% change between the two
groups (from 40% to 28%, corresponding to an odds ratio of 0.6), a total sample size
of 488 mothers would be required at 80% power and alpha = 0.05. To account for a 15%
dropout, this number is increased to 560 (280 per group). The duration of the trial
is expected to be 36–40 months.
The use of a galactogogue often becomes the measure of choice for mothers in the presence of insufficient breast milk production, particularly when the other techniques are unsuccessful. EMPOWER is designed to provide valuable information in guiding the practices for this high-risk group of infants and mothers. The results of this trial will also inform both mothers and clinicians about the choices available to increase and maintain sufficient breast milk.
Clinical Trials.gov Identifier: NCT01512225